Your CGM Knows You Ate. It Can’t Tell What You Ate.
How much of a meal signal is there in glucose data, and what can you do with it? This article describes a deep dive into a large dataset and tells us what it finds.
Diabetes
Beyond Carb Counting: Boost’s Evolution — and the Limits of “Fully Closed Loop”
An update on Boost, how it helps remove carb counting, and the techniques and mechanisms we’ve used to try and get there.
Bolt AI into your loop and you might just have become a medical device manufacturer
Embedded AI is starting to appear in open source AID systems, offered as copy and paste, bring your own key, or a service the project runs. A year of measuring these models says the clinical risk is much the same in all three. The regulatory position is not, and the intuition about which is safest runs backwards.
The world’s first digital endo that asks AI to fix your AID settings, and why you should keep your money.
Ask once and you get an answer. Ask fifty times and you get eighteen different pairs of safety limits, a headline that flips one time in five, and an app that accepts them all. Inside the £4.49 app that turns your diabetes data into chatbot advice on your OS-AID settings.
A world of pure imagination: AI, diabetes and the data we can’t get at
Search the app stores for diabetes and AI and you will find a remarkable number of applications doing exactly one thing. You point a camera […]
Why is the cheese sandwich the downfall of AI carb counting, even with “3D scanning”?
A slightly rhetorical question, I’ll admit, but a pertinent one. Once again, I have been trying out the latest (read most heavily pushed on Facebook […]
The Libre Duo. A platform prototype to move care from the hospital to the home?
Abbott has put glucose and ketones on the same wearable, and the launch coverage is all about DKA. Worth having if you’re on a pump, which is fine as far as it goes, but it misses the bit that makes this interesting. Because if you look at what Abbott has actually built across its other divisions, and what they’ve patented alongside it, the Libre Duo doesn’t really look like a ketone sensor. It looks like the platform prototype and the first visible piece of an infrastructure designed to move chronic disease care out of outpatients and into the home. And the policy environment for that shift has just been locked in on both sides of the Atlantic for the next five years.
Five AI models, three users, one finding: the settings came from the textbook, not the data
We took Nightscout data from three people and gave it to 5 Large Language Models with a detailed prompt to see how they would respond.
The results weren’t what I was expecting.
I Asked AI to Count My Carbs 27,000 Times. It Couldn’t Give Me the Same Answer Twice.
Ask ChatGPT to estimate the carbs in your lunch. Now ask it again. And again. Five hundred times. You’d expect the same answer each time. […]
100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure
Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn’t it a cure yet, and how does it fit into the actual blueprint of a functional cure?